STUDIES.
SCIENTIFIC RESEARCH
IN FOCUS.
GLARIUS-Trial (randomized phase 2 study of bevacizumab/irinotecan therapy versus standard therapy in the primary treatment of newly diagnosed MGMT-unmethylated glioblastoma)
GLARIUS-Trial (randomized phase 2 study of bevacizumab/irinotecan therapy versus standard therapy in the primary treatment of newly diagnosed MGMT-unmethylated glioblastoma)
In the GLARIUS study, there was a 2:1 randomization between the experimental arm (bevacizumab + irinocetan) versus the standard arm. As the study only included patients with an unmethylated MGMT promoter and temozolomide is at best only very slightly effective in this population, temozolomide therapy was not required in the experimental arm.